Board of Directors

Mr. John Drake is the President and Founding Partner, Drake Goodwin Corporation in London, Ontario. Drake Goodwin Corporation is a London, Canada investment firm with diverse interests in financial services, real estate development and manufacturing. Drake Goodwin has realized substantial investment gains over the first 22 years of its history. Mr. Drake is Chairman of the DGM Bank & Trust Inc. of Barbados. Mr. Drake is also a director of Discovery Air Inc., a TSX Venture-listed company. Mr. Drake received his B.A. and LL.B. degrees from the University of Western Ontario.

Mr. Alexander is a Professional Corporate Director and prior to this role, served as Chief Financial Officer of various Canadian public companies for 15 years, the most recent being from 1999 to 2004 as Executive Vice President and Chief Financial Officer of Trojan Technologies Inc., an international environmental technology company.  Mr. Alexander is a Chartered Accountant and a Chartered Director, having graduated in 2009 from the Director’s College, a joint venture between McMaster University and the Conference Board of Canada.

Alison Silva is the President, Chief Executive Officer and a Director of Critical Outcome Technologies, Inc. Previously, she was a co‐founder, Executive Vice President and Chief Operating Officer at Synlogic, Inc. where she lead the regulatory strategy, drug development, and operational aspects of the company’s focus on the discovery and development of engineered therapeutic probiotics. Alison is also a co‐founder of The Orphan Group, a specialty consulting company focused on assisting companies with developing and implementing their orphan drug strategy and product lifecycle management.

Alison previously held the position of Chief Operating Officer at SLA Pharma, a GI‐oncology focused biotech company, where she was responsible for heading up U.S. corporate and clinical operations for their pipeline of orphan drug candidates. Prior to joining SLA Pharma, Alison was Vice President of Drug Development at Marina Biotech through its acquisition of Cequent Pharmaceuticals in 2010, where she held the same role since 2007. Alison began her career in drug development in clinical operations with various positions at Pfizer, Massachusetts General Hospital, and the University of Massachusetts. Alison holds a Bachelor’s degree from Clark University and a Master’s degree from Clark University and UMass Medical Center.

Mr. B. Maruzzo is currently President of TecnhnoVenture Inc., a consulting company specializing in providing services to early stage technology companies. He has worked with a variety of public and private high technology companies in both the technology and life science sectors, where he held positions in a range of areas including business development, corporate development, investor relations, engineering management and general management. He has also worked in the venture capital field sourcing, assessing and making investments in early-stage, technology-based companies in Canada and the US. Prior to joining TecnhnoVenture Inc, Mr. Maruzzo worked for such companies as GeneNews, Empyrean Diagnostics, International Murex Technologies Corporation, and Visible Genetics Inc. Mr. Maruzzo holds a BASc in Electrical Engineering from the University of Waterloo, an MASC in Biomedical Engineering from the University of Toronto and an MBA from the University of Toronto.

Dave is a co-founder of KFL Capital Management Ltd. (“KFL”) and its CEO. Dave also serves as President & CEO of KFL Investment Management Inc. (“KFL IMI”), the parent company of KFL.

Prior to KFL, Dave was a Managing Director at BMO Nesbitt Burns where he managed one of the largest retail brokerage offices in Canada.  This position was the most recent in a 15-year career in financial services during which he worked at another retail brokerage, TD Waterhouse, and in distribution at AIM Trimark Investments.

Dave is also an active private investor and co-founded Entertech Systems Inc. and Actual ID, companies that make biometric access, control and time and attendance technology and software.  Mr. Sanderson is also a General Partner in a small venture fund that has investments in the medical device and security equipment industries.

Dave recently served on the Board of Directors of London Health Sciences Centre from 2009-2012 and the Fowler Kennedy Sports Injury Clinic from 2009-2012.

Dave has a business degree from The Richard Ivey School of Business at Western University and a law degree from Queen’s University. He was called to the Ontario Bar in 1992 and practiced at Stikeman, Elliott in Toronto for seven years as a corporate, commercial, and insolvency litigator.

Dr. Yoo is the Research Director of the Department of Otolaryngology at Western University; holds cross appointments in the Department of Oncology and the Department of Medical Biophysics; is Chair of the Department of Otolaryngology, Chief of the Division of Head & Neck Oncology and Reconstructive Surgery, a Member of the Cancer Care Ontario Head and Neck Oncology Disease Site Council and an Executive member of the Canadian Head and Neck Oncology Research Group.

Dr. Chowrira has a strong track record in the biopharmaceutical industry with more than 20 years of experience, combining a unique blend of research, corporate development, operations, financing, legal and licensing expertise. Dr. Chowrira is currently the President of Synlogic Inc., a U.S. biopharmaceutical company focused on synthetic biotics, where he has overseen and managed corporate and business development, alliance management, and financial and legal operations since September 2015. Prior to joining Synlogic, Dr. Chowrira was the Chief Operating Officer of Auspex Pharmaceuticals, which was acquired by Teva Pharmaceuticals in the spring of 2015. Previously, he was President and Chief Executive Officer of Addex Therapeutics, a biotechnology company publicly‐traded on the SIX Swiss Exchange. Before that, he held various leadership and management positions at Nektar Therapeutics, Merck & Co., Sirna Therapeutics, (acquired by Merck & Co.) and Ribozyme Pharmaceuticals. Dr. Chowrira has a J.D. from the University of Denver’s Sturm College of Law, a Ph.D. in Molecular Biology from the University of Vermont College of Medicine, a M.S. in Molecular Biology from Illinois State University, and a B.S. in Microbiology from the University of Agricultural Sciences, Bangalore, India.